{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:05:41Z","timestamp":1772060741893,"version":"3.50.1"},"reference-count":32,"publisher":"Baishideng Publishing Group Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Hepatol"],"abstract":"BACKGROUND<\/jats:p>\n Metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic fibrosis, and cirrhosis are major risk factors for hepatocellular carcinoma (HCC), yet current blood-based diagnostic assays lack sufficient accuracy for routine clinical use. Identifying a non-invasive molecular signature that accurately detects liver disease could improve early diagnosis and monitoring. We hypothesized that the Liver FibraChek Dx\u00a9 serum assay could discriminate MASLD and HCC from healthy controls using a multiplex biomarker-based algorithm.<\/jats:p>\n AIM<\/jats:p>\n To evaluate the diagnostic performance of the Liver FibraChek Dx\u00a9 assay for detecting MASLD and HCC.<\/jats:p>\n METHODS<\/jats:p>\n This was a prospective, single-center study conducted in a United States tertiary care setting. Serum samples were collected from 45 participants (14 MASLD, 19 HCC, 12 healthy controls) with liver histology confirmed by biopsy. The Liver FibraChek Dx\u00a9 algorithm integrates weighted values of aspartate aminotransferase, alanine aminotransferase, taurocholic acid, L-tyrosine, platelet count, and patient age to generate a risk score. Wilcoxon rank sum tests were used to assess associations with histologic diagnosis, and receiver operating characteristic (ROC) curves quantified diagnostic performance.<\/jats:p>\n RESULTS<\/jats:p>\n Liver FibraChek Dx\u00a9 risk scores were significantly elevated in MASLD and HCC compared to controls (median: 6.92 \u00b1 3.86 vs 3.61 \u00b1 1.67, P < 0.001). The area under the ROC curve was 0.890 (95%CI: 0.776\u20131.000) for distinguishing diseased from healthy individuals. Sensitivity was 93.9%, specificity 75.0%, positive predictive value 91.1%, negative predictive value 81.8%, and overall accuracy 88.9%.<\/jats:p>\n CONCLUSION<\/jats:p>\n The Liver FibraChek Dx\u00a9 assay accurately detects liver disease and shows promise as a non-invasive tool for diagnosing and monitoring MASLD and HCC.<\/jats:p>","DOI":"10.4254\/wjh.v17.i6.106481","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:44:32Z","timestamp":1750844672000},"source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic performance of Liver FibraChek Dx\u00a9<\/sup>, a blood-based test for the non-invasive detection of liver cirrhosis and cancer"],"prefix":"10.4254","volume":"17","author":[{"given":"Fernando","family":"Siguencia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michitaka","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Pandyarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Bresee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekihiro","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles J","family":"Rosser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240542"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.060"},{"key":"B3","unstructured":"Brenner DA. Reversibility of liver fibrosis. Gastroenterol Hepatol (N Y) 2013; 737-739"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00372-7"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2018.01.009"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cld.740"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01595-w"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.patrec.2005.10.010"},{"key":"B9","unstructured":"United States Centers for Disease Control NCfHS. Chronic Liver Disease and Cirrhosis. 2023. Available from: https:\/\/www.cdc.gov\/nchs\/fastats\/liver-disease.htm"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00799-z"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101167"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12896"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.002"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.011"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21496"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2021.41.1.16"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-022-01890-y"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136900"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.hepres.2005.12.006"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2010.03.006"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12050440"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19841101)54:9<1875::aid-cncr2820540918>3.0.co;2-o"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11247337"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/35.7.1399"},{"key":"B25","unstructured":"Campollo O, Sprengers D, McIntyre N. The BCAA\/AAA ratio of plasma amino acids in three different groups of cirrhotics. Rev Invest Clin 1992; 513-8"},{"key":"B26","unstructured":"Fulenwider JT, Nordlinger BM, Faraj BA, Ivey GL, Rudman D. Deranged tyrosine metabolism in cirrhosis. Yale J Biol Med 1978; 625-633"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.934648"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103068"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00601-8"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.5b00217"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.02.030"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0327"}],"container-title":["World Journal of Hepatology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v17\/i6\/106481.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v17\/i6\/106481.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:44:46Z","timestamp":1750844686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v17\/i6\/106481.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":32,"journal-issue":{"issue":"6"},"alternative-id":["106481"],"URL":"https:\/\/doi.org\/10.4254\/wjh.v17.i6.106481","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}